Every peptide deep-dive, head-to-head comparison, long-form guide, and regulatory log entry in one place. Each entry shows the evidence tier so you can sort claims by what the data actually supports.
Standalone research pages for each peptide in the catalog — mechanism, evidence landscape, regulatory status, and honest verdict. Evidence-tier badges mirror each page's published human-data strength.
Zero published human RCTs, animal data dominated by a single research lab (Sikiric), the FDA/WADA regulatory position, and what the evidence actually supports.
Animal evidence on actin-driven cell migration and angiogenesis, zero human RCTs, FDA orphan-drug status for corneal repair, WADA prohibition, and what the evidence actually supports.
Copper-binding tripeptide with stronger evidence for topical use than injectable. Honest breakdown of what the data actually shows, including the 2012 Lorentic RCT.
Selective GH secretagogue — mechanism, zero human RCTs for musculoskeletal or anti-aging use, off-label dosing reality, and WADA S2 prohibition for athletes.
Synthetic GHRH 1–29 analog — upstream GH-axis partner to Ipamorelin. Diagnostic-only RCT trail (Reutens 1996, Walker 1994) and zero efficacy data for adult anti-aging. Withdrawn 2008; WADA S2.
Long-acting GHRH analog (with or without DAC), same upstream receptor as Sermorelin. The half-life distinction is pharmacokinetic only — zero human RCTs for adult anti-aging / body-comp / sleep; the mechanism class is anchored to Walker 1994 (PMID 7527273, reused); never FDA approved; WADA S2.
Strong human RCT evidence (STEP, SUSTAIN, SELECT), FDA approval, mechanism of action, real-world cardiovascular outcomes, and what the data actually supports.
Side-by-side evidence breakdowns when two peptides overlap on use case, mechanism, or risk. Use these when one peptide isn't an obvious fit and the decision depends on what the alternative actually delivers.
The complete index of live head-to-head comparisons, with evidence-tier badges, evidence-grounded summaries, and the quick-reference table covering every peptide in the catalog.
Two healing peptides with overlapping but non-identical evidence trails — claims table (reused PMIDs), mechanism/risk/dosing matrix, and a when-to-choose verdict.
Hormonal secretagogue vs topical copper peptide — different categories, but the question "is the recovery worth the risk?" pulls both into a buyer's decision. Verdict, dosing reality, and risk-tier matrix.
Healing-vs-longevity comparison — tendon/GI evidence vs GH-pulse/recovery-sleep axis. Dosing, half-life, risk-tier matrix, and when-to-choose verdict grounded in reusable PMIDs.
Healing vs. skin regeneration — BPC-157's systemic angiogenic animal evidence vs GHK-Cu's topical copper-tripeptide moderate human evidence (Lorentic 2012). Verdict and dosing/risk matrix for each delivery route, with PMIDs reused from the underlying deep-dives only.
Two GH-axis peptides — upstream GHRH 1–29 analog (Sermorelin) vs selective ghrelin-receptor agonist (Ipamorelin). Both share WADA S2, both have zero human efficacy RCTs for the indications driving online interest, with PMIDs reused from the underlying deep-dives only.
Two GHRH-receptor analogs with different half-life profiles — both have human pharmacodynamic or diagnostic-stimulation evidence, but zero efficacy RCTs for adult anti-aging or body-composition claims.
Long-acting GHRH analog (CJC-1295, with or without DAC) vs selective ghrelin-receptor GHRP (Ipamorelin, Raun 1998 PMID 9783708). Different GH-axis receptors, same WADA S2, both zero human efficacy RCTs for adult anti-aging / body-comp / sleep, PMIDs reused from underlying deep-dives only.
Tissue-repair vs skin-regeneration contrast — TB-500's systemic animal evidence vs GHK-Cu's topical human RCTs (Lorentic 2012, Draelos 2006). Asymmetric verdict across delivery routes, with PMIDs reused from the underlying deep-dives only.
Local wound-healing & NO-pathway (BPC-157, Sikiric-lab animal data, WADA S0) vs upstream GHRH-receptor GH-pulse amplification (Sermorelin, Reutens 1996 / Walker 1994 narrow-window human pharmacodynamics, WADA S2). Anti-aging-stack case-split with WADA-asymmetric verdict, PMIDs reused from the underlying deep-dives only.
TB-500's tissue-repair and cell-migration animal evidence vs Ipamorelin's GH-axis pharmacodynamics. Neither has human efficacy RCTs for the marketed outcomes; WADA categories differ (S0 vs S2).
Extended guides for the most-searched peptides — the pages that go past mechanism into dosing reality, risks-unknowns, and a buyer-focused verdict.
A long-form guide to BPC-157: 5-pathway mechanism walk-through, evidence map by indication, dosing matrix (community vs Sikiric rodent vs Lee & Burgess 2025 IV), risks, FDA/WADA status, FAQ, and honest verdict.
A long-form guide to TB-500 (Thymosin Beta-4): 5-pathway mechanism walk-through, evidence map by indication, dosing matrix (community vs racehorse vs Goldstein rodent vs the missing human PK study), risks, FDA orphan-drug / WADA status, FAQ, and honest verdict.
A long-form guide to Ipamorelin (selective ghrelin-receptor GHRP): 5-pathway mechanism walk-through (GHS-R1a binding, somatotroph GH pulse, cortisol/prolactin selectivity, GHRH-analog synergy, downstream effects), evidence map by indication (Raun 1998 healthy-volunteer selectivity, GH-stimulation-test context, zero body-composition RCTs), dosing matrix (community vs Raun 1998 single-dose vs the missing chronic-dose human PK study), risks, FDA compounding gray zone / WADA S2 status, FAQ, and honest verdict.
A long-form guide to Sermorelin (synthetic GHRH 1–29 analog): 5-pathway mechanism walk-through (GHRH receptor binding, preserved pulsatility, FSH/LH/TSH non-cross-reactivity, GHRP synergy, downstream effects), evidence map by indication (Reutens 1996 / Walker 1994 narrow-window adult diagnostic-stim GH pulsatility, zero body-composition / anti-aging / sleep RCTs, 2008 US-market withdrawal), dosing matrix (pediatric diagnostic vs adult community vs missing chronic-dose human PK), risks, FDA compounding context / WADA S2 GH-Releasing Factors status, FAQ, and honest verdict.
A long-form guide to CJC-1295 (long-acting GHRH analog, with or without DAC): mechanism walk-through (same upstream GHRH-receptor pathway as Sermorelin with an extended pharmacokinetic window via Drug Affinity Complex), evidence map by indication (Reutens 1996 / Walker 1994 narrow-window GH-stim data; zero body-composition or anti-aging RCTs), dosing matrix (single-dose pharmacodynamic context vs. community twice-weekly protocols), risks, WADA S2 GH-Releasing Factors prohibition, FAQ, and honest verdict.
Dated regulatory actions affecting the catalog — FDA, compounding rulings, DOJ/SEC, state-board orders, and WADA prohibited-list updates.
A dated log of FDA actions, compounding pharmacy rulings, DOJ/SEC actions, and state board orders that affect BPC-157, TB-500, GHK-Cu, Ipamorelin, and GLP-1 peptides. Updated weekly.
The rubric behind every evidence-tier badge on the catalog — RCT count, peer review, sample size, and reproducibility. Read this if you want to evaluate our tier assignments (or the tier assignments other sites skip).
The four-criterion rubric we apply to every peptide: RCT count, peer-review status, sample size, and reproducibility across independent research groups. Worked examples for every tier.
Index pages that organize the rest of the library — the catalog view, the comparison reference, and the filterable research overview.
Full catalog of every peptide referenced across the site, with category tags and quick links into the deep-dive pages.
Sortable, filterable dashboard — filter by evidence tier (human RCT, animal, mechanistic) and sort by evidence strength, name, or risk profile.
Side-by-side peptide reference table covering primary use case, evidence tier, FDA status, WADA status, and risk profile — a quick lookup for buyer qualification.
This is a research library index, not medical advice. PeptideDecoded does not sell peptides, recommend vendors, provide dosing protocols, or make claims about safety or efficacy for any specific individual.
Work with a qualified physician who can evaluate your full medical history, current medications, and individual risk factors before making any decision about peptides — whether FDA-approved, compounded, or sold as research chemicals.